Racing in Collaboration
We work with researchers from all over the world, fund more than 100 grants annually and build collaborations so advances are shared and can build new breakthroughs.
Two Open Windows
Backed by JDRF supporters, T1D research has led to critical advances in two key areas. So promising is the work that scientists say they see two open windows, offering line of sight to potential cures. JDRF is accelerating our push toward those two windows, aiming to lift science through those windows and to the other side.
Beta Cell Research and Immune Therapy
The first key area of work is Beta Cell Research — which includes Beta Cell Replacement and Beta Cell Regeneration.
We know that when someone has T1D, their own body turns on itself, attacking and destroying the cells that create insulin. These cells are called beta cells. Understanding the role of beta cells, was a breakthrough that created an early window. We know that if we can save Beta Cells, we can cure T1D.
The second key area is Immune Therapy. T1D is one of the only major autoimmune diseases that still does not have a drug therapy to stave off, slow or cure the illness. But we are g etting close.
Our work also is critically focused on Prevention, as preventing the onset or progress of T1D will cure the disease for so many.
Beta Cell Replacement
An experimental therapy that involves implanting protected insulin-producing cells inside the body.
Beta Cell Regeneration
Disease-modifying therapies that promote the survival of insulin-producing beta cells.
Immune Therapies
Treatments that “turn off” the body’s autoimmune attack against its insulin-producing beta cells.
Prevention
An effort to prevent T1D through the development of a childhood vaccine, broader screening and improved ability to predict the disease.
Aaron K. Kowalski, Ph.D.
JDRF President and CEO
This is a pivotal time for T1D research — and so many of our supporters and partners are helping us accelerate forward toward finding cures.